Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients-Reference-Cited by-同舟云学术

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

Published:2016-12-19 Issue:4 Volume:52 Page:580-587
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Andersson B S,Thall P F,Valdez B C,Milton D R,Al-Atrash G,Chen J,Gulbis A,Chu D,Martinez C,Parmar S,Popat U,Nieto Y,Kebriaei P,Alousi A,de Lima M,Rondon G,Meng Q H,Myers A,Kawedia J,Worth L L,Fernandez-Vina M,Madden T,Shpall E J,Jones R B,Champlin R E

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/bmt2016322.pdf

Reference56 articles.

1. Thomas ED. A history of allogeneic hematopoietic cell transplantation. In: Appelbaum FR, Forman SJ, Negrin RS, Blume KG (eds). Thomas’ Hematopoietic Cell Transplantation, 4th edn. Wiley-Blackwell: Oxford, UK, 2009, pp 3–7.

2. Thomas ED, Buckner CD, Banaji M, Clift RA, Fefer A, Elurnoy N et al. One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic marrow transplantation. Blood 1977; 49: 511–533.

3. Russell JA, Tran HT, Quinlan D, Chaudhry A, Duggan P, Brown C et al. Once-daily intravenous busulfan given with fludarabine as conditioning for allogeneic stem cell transplantation: study of pharmacokinetics and early clinical outcomes. Biol Blood Marrow Transplant 2002; 8: 468–476.

4. de Lima M, Couriel D, Thall PF, Wang X, Madden T, Jones R et al. Once-daily intravenous busulfan and fludarabine: clinical and pharmacokinetic results of a myeloablative, reduced-toxicity conditioning regimen for allogeneic stem cell transplantation in AML and MDS. Blood 2004; 104: 857–864.

5. Russell JA, Savoie ML, Balogh A, Turner AR, Larratt L, Chaudhry MA et al. Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400cGy total-body irradiation, and thymoglobulin. Biol Blood Marrow Transplant 2007; 13: 814–821.

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT);Bone Marrow Transplantation;2024-09-13

2. Fludarabine Melphalan, Reduced-dose Busulfan Versus Fludarabine, Melphalan, Full-dose Busulfan in Patients Receiving Cord Blood Transplantation;Transplantation Proceedings;2024-09

3. Effect of clofarabine and fludarabine exposure on outcome after pediatric allogeneic hematopoietic cell transplantation;Blood Neoplasia;2024-09

4. Evaluating clinically translatable conditioning for platelet gene therapy in murine hemophilia A with inhibitors;Journal of Thrombosis and Haemostasis;2024-08

5. Simulation-Based Optimization of Sampling Schedules for Model-Informed Precision Dosing of Once-Daily and 4-Times-Daily Busulfan in Pediatric Patients;Therapeutic Drug Monitoring;2024-06-14